trending Market Intelligence /marketintelligence/en/news-insights/trending/BAXQFVP5gonjr67cahzncg2 content esgSubNav
In This List

US FDA approves Glenmark's generic hypertension drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


US FDA approves Glenmark's generic hypertension drug

Glenmark Pharmaceuticals Ltd. secured the U.S. Food and Drug Administration approval to market a generic version of Benicar.

Benicar is Daiichi Sankyo Co. Ltd.'s hypertension drug, and Glenmark will manufacture it at its facility in Goa, India.

Benicar generated $950 million in sales during the 12 months ending March, according to IMS Health data.